Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VA Peg-Intron registry

Executive Summary

Schering-Plough's Peg-Intron (peginterferon alfa-2b) patient registration program will last six to 12 months, Department of Veterans Affairs estimates. VA has established its own registration program, which does not include patient-specific data, because it objected to the amount of information Schering's program was collecting 1("The Pink Sheet" Nov. 5, 2001, p. 20)...

You may also be interested in...



PEG-Intron Access Program Requires ID Number, Designed To Ensure Supply

Schering-Plough is implementing a prescription tracking program for PEG-Intron to ensure that existing patients will have adequate supply of peginterferon alfa-2b

QUOTED. 22 September 2020. Francis deSouza.

Illumina announced on 21 September it will buy back Grail, which is planning to commercialize its multi-cancer early detection blood test Galleri in 2021. See what Illumina’s CEO Francis deSouza said about it here.

Gottlieb vs Azar vs Califf vs Gottlieb: The Public Fight Over How The US FDA Should Operate

Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel